1. Home
  2. BIIB vs RBLX Comparison

BIIB vs RBLX Comparison

Compare BIIB & RBLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • RBLX
  • Stock Information
  • Founded
  • BIIB 1978
  • RBLX 2006
  • Country
  • BIIB United States
  • RBLX United States
  • Employees
  • BIIB N/A
  • RBLX N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • RBLX EDP Services
  • Sector
  • BIIB Health Care
  • RBLX Technology
  • Exchange
  • BIIB Nasdaq
  • RBLX Nasdaq
  • Market Cap
  • BIIB 25.1B
  • RBLX 36.7B
  • IPO Year
  • BIIB 1991
  • RBLX 2021
  • Fundamental
  • Price
  • BIIB $150.03
  • RBLX $59.04
  • Analyst Decision
  • BIIB Buy
  • RBLX Buy
  • Analyst Count
  • BIIB 27
  • RBLX 23
  • Target Price
  • BIIB $252.20
  • RBLX $54.77
  • AVG Volume (30 Days)
  • BIIB 1.4M
  • RBLX 9.1M
  • Earning Date
  • BIIB 02-11-2025
  • RBLX 02-05-2025
  • Dividend Yield
  • BIIB N/A
  • RBLX N/A
  • EPS Growth
  • BIIB 10.05
  • RBLX N/A
  • EPS
  • BIIB 11.06
  • RBLX N/A
  • Revenue
  • BIIB $9,607,500,000.00
  • RBLX $3,363,735,000.00
  • Revenue This Year
  • BIIB N/A
  • RBLX $59.15
  • Revenue Next Year
  • BIIB N/A
  • RBLX $20.45
  • P/E Ratio
  • BIIB $13.57
  • RBLX N/A
  • Revenue Growth
  • BIIB N/A
  • RBLX 27.98
  • 52 Week Low
  • BIIB $150.48
  • RBLX $29.55
  • 52 Week High
  • BIIB $268.30
  • RBLX $61.05
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 25.52
  • RBLX 67.17
  • Support Level
  • BIIB $153.69
  • RBLX $55.61
  • Resistance Level
  • BIIB $158.20
  • RBLX $61.05
  • Average True Range (ATR)
  • BIIB 3.58
  • RBLX 2.09
  • MACD
  • BIIB 0.16
  • RBLX 0.49
  • Stochastic Oscillator
  • BIIB 0.62
  • RBLX 84.66

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About RBLX Roblox Corporation

Roblox operates an online video game platform with 80 million daily active users that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning $3.5 billion in bookings in 2023 through in-game purchases and advertising while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers than creating new games or franchises.

Share on Social Networks: